CNBC March 5, 2025
Key Points
– Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market.
– MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly, which are weekly injectables.
– One phase three trial is examining Amgen’s drug in around 3,500 people with obesity or who are overweight without Type 2 diabetes, while a second studies MariTide in 999 patients who are obese or overweight and have Type 2 diabetes
Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another...
Today's Sponsors
Today's Sponsor